Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Triple Negative Breast Cancer (TNBC): early-phase trial registry
10 of 15 indexed Triple Negative Breast Cancer (TNBC) trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #1,140 of 28,707 conditions by registered trial count.
15 US clinical trials · 10 currently recruiting · #1,140 of 28,707 conditions by registered trial count
Triple Negative Breast Cancer (TNBC): 15 US clinical trials tracked, 10 recruiting.
Triple Negative Breast Cancer (TNBC) is the subject of 15 registered US clinical trials on ClinicalTrials.gov, 10 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 15 in Phase 1-2 (earlier-stage). The most active sponsor is Antonio Giordano, MD, running 1 of these trials.
Enrollment posture brief
Registry condition triple-negative-breast-cancer-tnbc
OPEN 10 | RECR 67% | LATE 0 | EARLY 15 | RANK #1140 | SPON 1
Volume-matched condition peers
Nearest open-share peer: Acute Hypoxemic Respiratory Failure (67% recruiting · 6 trials)
Triple Negative Breast Cancer (TNBC) lists 10 open slots (67% of 15 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Triple Negative Breast Cancer (TNBC) on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Triple Negative Breast Cancer (TNBC) is recruiting above its size-band peers.
10 of 15 indexed trials (66.7%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of Triple Negative Breast Cancer (TNBC) trials is spread across many organizations.
Antonio Giordano, MD accounts for 1 of 15 trials (6.7%). 15 distinct sponsors appear on at least one study for this condition label.
-
Typical Triple Negative Breast Cancer (TNBC) enrolment sits around 144 participants.
Median target enrolment is 144 among the 15 trials that report a genuine target (sentinel values excluded). 6 of those (40%) plan for fewer than 100 participants.
-
Triple Negative Breast Cancer (TNBC) research is mostly interventional.
15 interventional and 0 observational studies make up this index (100% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
15 total, page 1 of 1
Study of XB010 in Subjects With Solid Tumors
Exelixis
NCT06545331
A Study of NX-1607 in Adults With Advanced Malignancies
Nurix Therapeutics
NCT05107674
Study to Assess GTAEXS617 in Participants With Advanced Solid Tumors
Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals
NCT05985655
A Study With NKT5097 for Adults With Advanced/Metastatic Solid Tumors
NiKang Therapeutics
NCT07029399
A Study of [225Ac]Ac-AKY-1189 in Patients With Solid Tumors
Aktis Oncology
NCT07020117
A Phase 1 Study of NRM-823 in Participants With Locally Advanced or Metastatic Refractory Solid Tumors
Normunity AccelCo
NCT07182149
JAB-2485 Activity in Adult Patients With Advanced Solid Tumors
Jacobio Pharmaceuticals Co.
NCT05490472
PQ203 in Advanced Malignant Tumors Including Triple Negative Breast Cancer
ProteinQure
NCT07190469
PREDICT-RD: ctDNA Surveillance in TNBC With Residual Disease
UNC Lineberger Comprehensive Cancer Center
NCT07069595
A Study to Assess CLBR001+ABBV-461 in Subjects With Locally Advanced or Metastatic Breast Cancer
Calibr, a division of Scripps Research
NCT06878248
A Study to Determine the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ABBV-927 With ABBV-368, Budigalimab (ABBV-181) and/or Chemotherapy in Participants With Locally Advanced or Metastatic Solid Tumors
AbbVie
NCT03893955
A Study of ADRX-0706 in Select Advanced Solid Tumors
Adcentrx Therapeutics
NCT06036121
Study of the CHK1 Inhibitor BBI-355, an ecDNA-directed Therapy (ecDTx), and the RNR Inhibitor BBI-825, in Subjects With Tumors With Oncogene Amplifications
Boundless Bio
NCT05827614
Onvansertib + Paclitaxel In TNBC
Antonio Giordano, MD
NCT05383196
OCTANE: Adjuvant Liposomal Doxorubicin and Carboplatin for Early-stage Triple-negative Breast Cancer
Mridula George, MD
NCT05949021
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 13 |
| Phase 2 | 2 |
Top Sponsors
Named interventions
Most-linked intervention names on Triple Negative Breast Cancer (TNBC) records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Triple Negative Breast Cancer (TNBC) trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Triple Negative Breast Cancer (TNBC) page
15 registered trials, 10 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 10 Triple Negative Breast Cancer (TNBC) trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Antonio Giordano, MD sponsors the most Triple Negative Breast Cancer (TNBC) trials on record, review their full trial history before evaluating a specific study. See Antonio Giordano, MD's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Triple Negative Breast Cancer (TNBC) condition card totals 15 registered trials; most-linked intervention Paclitaxel; top US site state Texas. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.